AR063073A1 - Inhibidor de la activacion de stat 3/5 - Google Patents
Inhibidor de la activacion de stat 3/5Info
- Publication number
- AR063073A1 AR063073A1 ARP070104333A ARP070104333A AR063073A1 AR 063073 A1 AR063073 A1 AR 063073A1 AR P070104333 A ARP070104333 A AR P070104333A AR P070104333 A ARP070104333 A AR P070104333A AR 063073 A1 AR063073 A1 AR 063073A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituent
- lower alkyl
- alkyl
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Estos compuestos son utiles para enfermedades autoinmunes, diabetes, SNC, cáncer. Reivindicacion 1: Un inhibidor de la activacion de STAT3/5 caracterizado porque contiene un compuesto aromático representado por la formula general (1) o una de sus sales como un ingrediente activo en donde X1 representa un átomo de nitrogeno o un grupo -CH=, R1 representa un grupo Z-R6, Z representa un grupo -N(R8)-B-, -B-N(R9)-, -B0-O-, [Formula 2], -CO-, -CH(OH)-, -N(R9a)-CO-N(R9b)-, -N=CH-, -N(R10a)-SO2- (B22a)e-, alquenileno inferior, -NHCO-B1-, -NHCO-B2-(W)u-, B0-O-B19a, [formula 3]), [formula 4], -SO2-N(R10b), -S-, alquinileno inferior, alquileno inferior, -N(R8d)- o -CO-NH-B18a-; R8 representa un átomo de H, un grupo alquilo inferior que puede tener un grupo alcoxi inferior como un sustituyente, alcanoilo inferior, alquil inferior-sulfonilo o fenilalquilo inferior, B representa un grupo -CO- o alquileno inferior, B0 representa un grupo alquileno inferior, B1 representa un grupo alquenileno inferior que puede tener un grupo fenilo como sustituyente, B2 representa un grupo alquileno inferior que puede estar sustituido con un grupo seleccionado del grupo que consiste en un grupo alcoxi y un grupo fenilo, R9a representa un átomo de H o un grupo alquilo inferior, R9b representa un átomo de H o un grupo alquilo inferior, R10a representa un átomo de hidrogeno o un grupo alquilo inferior, B22a representa un grupo alquileno inferior o un grupo alquenileno inferior, e representa 0 o 1, B18a representa un grupo alquileno interior, B19a representa un grupo alquileno inferior, B20a representa un grupo alquileno inferior, B21a representa un grupo alquileno inferior, k representa 2 o 3, c representa 0 o 1, d' representa 0 o 1, R10b representa un átomo de hidrogeno o un grupo alquilo interior, R8d representa un átomo de hidrogeno o un grupo alquilo inferior, W representa un átomo de oxígeno, un grupo -NH- o un átomo de azufre, u representa 0 o 1, R6 representa un grupo heterocíclico monocíclico, bicíclico o tricíclico saturado o insaturado de 5 a 10 miembros que tiene 1 a 4 átomos de nitrogeno, átomos de oxígeno o átomos de azufre (que pueden tener 1 a 3 sustituyentes que están seleccionados del grupo que consiste en un grupo oxo; alcoxi inferior que puede tener un átomo de halogeno como un sustituyente; alquilo inferior que puede tener un átomo de halogeno como un sustituyente; un átomo de halogeno; alquil inferior-sulfonilo; fenilo que puede estar sustituido con un grupo alquilo inferior que puede tener un átomo de halogeno en el anillo fenilo; alquil inferior-tio, pirrolilo, benzoílo; alcanoílo inferior; alcoxi inferior-carbonilo; y un grupo amino que puede tener un grupo seleccionado del grupo que consiste en un grupo alquilo inferior y un grupo alcanoílo inferior como un sustituyente, en el anillo heterocíclico) , un grupo adamantilo, naftilo (que puede tener 1 a 3 grupos seleccionados del grupo que consiste en un grupo alquilo inferior, un átomo de halogeno y un grupo amino que puede tener un grupo seleccionado del grupo que consiste en un grupo alquilo inferior y un grupo alcanoílo inferior como un sustituyente, en el anillo naftaleno), un grupo alquilo que puede tener un grupo alcoxi inferior como un sustituyente, cicloalquilo que puede estar sustituido con un grupo seleccionado del grupo que consiste en un grupo alquilo inferior sustituido con amino que puede tener un grupo alquilo inferior y un grupo alquilo inferior que puede tener un átomo de halogeno como un sustituyente, en el anillo cicloalquilo, alquenilo inferior que puede tener un átomo de halogeno como un sustituyente, alcanoilo inferior, benzoilo (que puede tener 1 a 3 grupos seleccionados del grupo que consiste en un grupo alquilo inferior que puede tener un átomo de halogeno y átomo de halogeno, como un sustituyente, en el anillo fenilo), alquilo inferior sustituido con un átomo de halogeno, cicloalquil-alquilo inferior o [Formula 5], R7 representa un átomo de hidrogeno, fenilo, carboxi, hidroxilo, un átomo de halogeno, alquilo inferior que puede tener un átomo de halogeno como un sustituyente, fenoxi, alcoxi inferior que puede tener un átomo halogeno como un sustituyente, alquilen inferior-dioxi, amino que puede tener, como un sustituyente, un grupo seleccionado del grupo que consiste en alquilo inferior, alcanoilo inferior, benzoilo y cicloalquilo, ciano, alcanoilo inferior que puede tener un átomo halogeno como un sustituyente, alquil inferior-sulfonilo, aminosulfonilo, alcoxi inferior-carbonilo, alcanoil inferior-oxi, alcoxi inferior-carbonilalquilo alquilo o un grupo heterocíclico saturado o insaturado e 5 o 6 miembros que tiene 1 a 4 átomo de N, O o S (que puede tener un grupo oxo en el anillo heterocíclico), m representa un numero entero de 1 a 5 (cuando m representa 2 a 5, dos a cinco R7 pueden ser idénticos o diferentes) y R2 representa H halogeno o alquilo inferior, Y representa un grupo -O-m, -N/R5)-, -CO-, -CH(OH)-, alquileno inferior, S(O)n- o -C(=N-OH)-, R5 representa un átomo de H, alquilo inferior, alcanoilo inferior, benzoilo, fenilalquilo inferior o cicloalquilo, n representa 0, 1 o 2; A representa un grupo de [formula 6] o un grupo [Formula 7], p representa 1 o 2, R3 representa un átomo de hidrogeno, alcoxi inferior, un átomo de halogeno, un grupo alquilo interior que puede tener un átomo de halogeno como un sustituyente, alcoxi inferior-carbonilo, carboxi, -CONR11R12, o un grupo ciano, en donde R11 y R12 pueden ser idénticos o diferentes y cada uno representa un átomo de hidrogeno, alquilo inferior, cicloalquilo o un grupo fenilo y R11 y R12, junto con el átomo de nitrogeno al que se unen, se pueden unir entre sí, directamente o a través de un átomo de nitrogeno, oxígeno o azufre para formar un anillo heterocíclico saturado de 5 a 7 miembros, R4 representa un grupo imidazolil-alquilo inferior, 1,2,4-triazolil-alquilo inferior, 1,2,3- triazolil-alquilo inferior, 1,2,5-triazolil-alquilo inferior, pirazolil-alquilo inferior, pirimidinil-alquilo inferior que puede tener un grupo oxo como un sustituyente en el anillo pirimidina, 3,5-dioxoisoxazolidin-4-iliden-alquilo inferior, 1,2,4- oxadiazolil-alquilo inferior que puede tener un grupo alquilo inferior como un sustituyente en el anillo 1,2,4-oxadiazolo, tiazolidinil-alquilo inferior que puede tener un grupo oxo como un sustituyente en el anillo tiazolidino, un grupo de [formula 8] un grupo de [formula 9] o un grupo -(T)1-N(R14)R15, R13 representa un átomo de H, alquilo inferior que puede tener un átomo halogeno como un sustituyente, alcanoilo inferior que puede tener un átomo halogeno como un sustituyente, alcoxi inferior- carbonilo, fenilalquilo inferior que puede tener un grupo alquilen inferior-dioxi como un sustituyente en el anillo fenilo, imidazolil-alquilo inferior, alcoxi inferior-carbonilalquilo alquilo, carboxi-alquilo inferior, benzoílo, alcanoílo inferior sustituido con amorfolino, piperazinilcarbonil-alquilo inferior que puede estar sustituido, en el anillo piperazina, con un grupo fenilalquilo inferior que puede tener un grupo alquilendioxi como sustituyente en el anillo fenilo, piperazinil- alcanoílo inferior que puede estar sustituido, en el anillo piperazina, con un grupo fenilalquilo inferior que puede tener un grupo alquilen inferior-dioxi como un sustituyente en el anillo fenilo, alquilo interior sustituido con morfolinocarbonilo o un grupo imidazolil-alcanoilo inferior, R13a representa un átomo de hidrogeno o un grupo hidroxilo, T representa un grupo alquileno inferior, -N(R17)-B3-CO-, -B19-N(R18)-CO-, -B4-CO-, Q-B5-CO-, -B6-N(R19-B7-CO-, -CO-B8-, -CH(OH)-B9-, -CO-B10-CO-, - CH(OH)-B11-CO-, -CO-, -SO2- o B23a-CO-CO-, en donde R17 representa un átomo de hidrogeno, alquilo interior, cicloalquilo, cicloalquilcarbonilo, alcanoílo inferior que puede tener un átomo de halogeno como un sustituyente, alquenilo inferior, alcanoilo inferior sustituido con amino que puede tener un grupo alquilo inferior corno un sustituyente o alquil inferior-sulfonilo, B3 representa alquileno inferior, B19 representa alquileno inferior, R18 representa un átomo de hidrogeno o alquilo inferior, B4 representa alquenileno inferior o alquileno inferior que puede tener un grupo hidroxilo como un sustituyente, Q representa un átomo de oxígeno o un grupo -S(O)n- (en donde n es el mismo que el descrito con anterioridad), B5 representa alquileno inferior, B6 representa alquileno inferior, R19 representa un átomo de H o alcanoílo inferior, B7 representa alquileno inferior, B8 representa alquileno inferior, B9 representa alquileno inferior, B10 representa alquileno inferior, B11 representa alquileno inferior, B23a representa alquileno inferior, l representa 0 o 1, R14 representa un átomo de H o alquilo que puede tener un grupo hidroxilo como sustituyente, R15 representa (2) alquilo sustituido con hidroxilo, (3) cicloalquilo que puede tener un grupo seleccionado del grupo que consiste en un grupo hidroxilo y alquilo inferior como un sustituyente, (4) fenoxialquilo inferior, (5) fenilo que puede estar sustituido, en el anillo fenilo, con 1 a 3 grupos seleccionados del grupo que consiste en un grupo alquilo inferior, alcoxi inferior que puede tener un átomo de halogeno como un sustituyente, un átomo de halogeno, aminoalcoxi inferior que puede tener un grupo alquilo inferior como un sustituyente, alquilo inferior sustituido con hidroxilo, fenilalquilo inferior, alquinilo inferior, grupo amino que puede tener un grupo alquil inferior-sulfonilo como sustituyente, alquil inferior-tio, cicloalquilo, feniltio, adamantilo, anilino que puede tener un átomo de halogeno como sustituyente en el anillo fenilo, alcoxi inferior-carbonilo, piperazinilo que puede tener un grupo alquilo inferior como un sustituyente en el anillo piperazina, pirrolidinilo que puede tener un grupo oxo como un sustituyente en el anillo pirrolidina, alcanoilamino inferior, ciano, y fenoxi, (6) fenoxi, (7) fenilalquilo inferior que puede estar sustituido, en
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006271172 | 2006-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063073A1 true AR063073A1 (es) | 2008-12-23 |
Family
ID=38896700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104333A AR063073A1 (es) | 2006-10-02 | 2007-10-01 | Inhibidor de la activacion de stat 3/5 |
Country Status (20)
Country | Link |
---|---|
US (2) | US8263599B2 (es) |
EP (2) | EP2612858A1 (es) |
JP (1) | JP5068821B2 (es) |
KR (1) | KR101148805B1 (es) |
CN (1) | CN101522657B (es) |
AR (1) | AR063073A1 (es) |
AU (1) | AU2007305511A1 (es) |
BR (1) | BRPI0717218A2 (es) |
CA (1) | CA2665000C (es) |
HK (1) | HK1131619A1 (es) |
IL (1) | IL197723A (es) |
MX (1) | MX2009003256A (es) |
MY (1) | MY150229A (es) |
NO (1) | NO20090856L (es) |
NZ (1) | NZ598061A (es) |
RU (1) | RU2489148C2 (es) |
TW (1) | TWI336699B (es) |
UA (1) | UA95978C2 (es) |
WO (1) | WO2008044667A1 (es) |
ZA (1) | ZA200901874B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2416608C2 (ru) | 2004-08-06 | 2011-04-20 | Оцука Фармасьютикал Ко., Лтд. | Ароматическое соединение |
EP1940786B1 (en) | 2005-09-16 | 2010-08-18 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
SI1957073T1 (sl) * | 2005-12-05 | 2014-08-29 | Otsuka Pharmaceutical Co., Ltd. A Corporation Organized Under The Laws Of Japan | Medicinsko zdravilo |
CN102099352B (zh) * | 2008-07-10 | 2014-02-26 | 一般社团法人创药分子Ip | 以喹啉甲酰胺衍生物为有效成分的stat3抑制剂 |
JP5688918B2 (ja) * | 2009-04-28 | 2015-03-25 | 大塚製薬株式会社 | 医薬組成物 |
PL2520575T3 (pl) * | 2009-12-28 | 2017-05-31 | General Incorporated Association Pharma Valley Project Supporting Organization | Związek 1,3,4-oksadiazolo-2-karboksyamidowy |
KR101411030B1 (ko) * | 2010-01-29 | 2014-06-30 | 오쓰까 세이야꾸 가부시키가이샤 | 항암제로서의 2 - 치환 피리딘 유도체 |
DK2624833T3 (en) * | 2010-10-04 | 2015-01-05 | Otsuka Pharma Co Ltd | 4- (Methylaminophenoxy) pyridin-3-yl-benzamide derivatives for the treatment of cancer |
WO2013020372A1 (zh) * | 2011-08-09 | 2013-02-14 | 中国科学院上海生命科学研究院 | 防治胰岛素抵抗和糖尿病的方法和试剂 |
TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
WO2013177534A2 (en) * | 2012-05-25 | 2013-11-28 | The Governing Council Of The University Of Toronto | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
CN103880707B (zh) * | 2012-12-19 | 2016-04-13 | 上海交通大学医学院 | Stat3小分子抑制剂及其应用 |
EP3019475A1 (en) * | 2013-07-08 | 2016-05-18 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
CN106536518B (zh) * | 2014-05-19 | 2020-05-12 | 勃林格殷格翰动物保健美国公司 | 驱蠕虫化合物 |
ES2764279T3 (es) | 2014-05-30 | 2020-06-02 | Governing Council Univ Toronto | Compuestos de sulfonamida y su uso como inhibidores de stat5 |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
WO2018200041A1 (en) * | 2017-04-26 | 2018-11-01 | University Of Cincinnati | Methods, agents, and compositions for the treatment of acute myeloid leukemia |
TWI650120B (zh) * | 2017-07-21 | 2019-02-11 | 寶騰生醫股份有限公司 | 一種醫藥組成物用於製備治療或預防個體感染病毒之藥物的用途 |
US10882821B1 (en) | 2017-09-26 | 2021-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes |
CN112203501A (zh) | 2018-06-01 | 2021-01-08 | 日洋服务株式会社 | 植物的栽培方法和植物的栽培装置 |
CN111763217B (zh) * | 2019-03-30 | 2022-06-28 | 上海凌达生物医药有限公司 | 一类噻吩并氮杂环类化合物、制备方法和用途 |
WO2020206424A1 (en) | 2019-04-05 | 2020-10-08 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
JP7268164B2 (ja) | 2019-08-06 | 2023-05-02 | 正月 白川 | 植物の栽培方法及び植物の栽培装置 |
RU2742188C1 (ru) * | 2020-07-22 | 2021-02-03 | Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. | Способ лечения оптической нейропатии у больных с отечным экзофтальмом |
CN117362206B (zh) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | 一类芳基磺酰胺类化合物、合成方法及用途 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE629102A (es) | 1961-03-29 | |||
US3715375A (en) | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
NL7111711A (es) | 1970-09-17 | 1972-03-21 | ||
GB1494117A (en) | 1974-11-02 | 1977-12-07 | Bayer Ag | Process for the preparation of acid amides |
DE2707660C2 (de) | 1977-02-23 | 1985-12-19 | Bayer Ag, 5090 Leverkusen | Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung |
DE2707659A1 (de) | 1977-02-23 | 1978-08-24 | Bayer Ag | Selbstvernetzbare polyurethane |
DE2812252A1 (de) | 1978-03-21 | 1979-10-04 | Bayer Ag | 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel |
US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
EP0500495A3 (en) | 1991-02-21 | 1993-04-07 | Ciba-Geigy Ag | Thermosetting composition |
ES2108855T3 (es) | 1992-07-21 | 1998-01-01 | Ciba Geigy Ag | Derivados de acido oxamico como agentes hipocolesteremicos. |
IL110159A0 (en) | 1993-06-30 | 1994-10-07 | Wellcome Found | Diaryl compounds, their preparation and pharmaceutical compositions containing them |
CA2223948A1 (en) | 1995-06-07 | 1996-12-19 | Rui Han | Chalcone retinoids and methods of use of same |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6613769B1 (en) | 1998-02-06 | 2003-09-02 | Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. | Tryptase inhibitors |
WO1999040083A2 (de) | 1998-02-06 | 1999-08-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Bifunktionelle tryptase-inhibitoren |
AR015733A1 (es) | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
TWI245035B (en) | 1998-06-26 | 2005-12-11 | Ono Pharmaceutical Co | Amino acid derivatives and a pharmaceutical composition comprising the derivatives |
DE69920923T2 (de) | 1998-07-24 | 2005-10-20 | Teijin Ltd. | Anthranilsäurederivate |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
AU2871900A (en) | 1999-02-04 | 2000-08-25 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
CO5160290A1 (es) | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
JP4609691B2 (ja) | 1999-07-01 | 2011-01-12 | 味の素株式会社 | 複素環化合物及びその医薬用途 |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
JP2001089450A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ピリジン誘導体含有医薬製剤 |
AU2001234089B2 (en) | 2000-02-15 | 2005-08-11 | Teijin Limited | Cancer remedy comprising anthranilic acid derivative as active ingredient |
CA2409827C (en) | 2000-05-22 | 2010-06-01 | Aventis Pharmaceuticals Products Inc. | Arylmethylamine derivatives for use as tryptase inhibitors |
GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
AU2001282874A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
EP1379127B1 (en) | 2000-09-28 | 2013-04-17 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
AU2002223626A1 (en) | 2000-10-20 | 2002-04-29 | Novartis Ag | Combinations of a thyromimetic compound and a statin |
EP1211235A3 (en) | 2000-11-30 | 2004-01-02 | JFE Chemical Corporation | Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof |
JP2004269356A (ja) | 2000-12-27 | 2004-09-30 | Ajinomoto Co Inc | 創傷部癒着防止剤 |
GB2374009A (en) | 2001-02-12 | 2002-10-09 | Novartis Ag | Method of treating hair loss |
TNSN03140A1 (fr) | 2001-06-20 | 2005-12-23 | Pfizer Prod Inc | Derives d'acides sulfoniques nouveaux. |
WO2003018586A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease |
BR0213452A (pt) | 2001-10-22 | 2004-11-09 | Pfizer Prod Inc | Derivados de piperazina com atividade antagonista receptora de ccr1 |
WO2003035602A1 (fr) | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Modulateurs lipidiques |
BR0307714A (pt) | 2002-02-15 | 2005-02-09 | Upjohn Co | Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns |
FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
JP2004035475A (ja) | 2002-07-03 | 2004-02-05 | Ajinomoto Co Inc | TGFβ作用抑制剤 |
WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
JP4939216B2 (ja) | 2003-07-24 | 2012-05-23 | レオ ファーマ アクティーゼルスカブ | 新規アミノベンゾフェノン化合物 |
RU2416608C2 (ru) * | 2004-08-06 | 2011-04-20 | Оцука Фармасьютикал Ко., Лтд. | Ароматическое соединение |
SI1957073T1 (sl) | 2005-12-05 | 2014-08-29 | Otsuka Pharmaceutical Co., Ltd. A Corporation Organized Under The Laws Of Japan | Medicinsko zdravilo |
TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
-
2007
- 2007-02-10 UA UAA200904059A patent/UA95978C2/ru unknown
- 2007-10-01 AR ARP070104333A patent/AR063073A1/es unknown
- 2007-10-02 AU AU2007305511A patent/AU2007305511A1/en not_active Abandoned
- 2007-10-02 WO PCT/JP2007/069645 patent/WO2008044667A1/en active Application Filing
- 2007-10-02 BR BRPI0717218-4A2A patent/BRPI0717218A2/pt not_active IP Right Cessation
- 2007-10-02 EP EP13153028.9A patent/EP2612858A1/en not_active Withdrawn
- 2007-10-02 NZ NZ598061A patent/NZ598061A/xx not_active IP Right Cessation
- 2007-10-02 CN CN200780036608.8A patent/CN101522657B/zh not_active Expired - Fee Related
- 2007-10-02 MX MX2009003256A patent/MX2009003256A/es active IP Right Grant
- 2007-10-02 US US12/311,500 patent/US8263599B2/en not_active Expired - Fee Related
- 2007-10-02 ZA ZA200901874A patent/ZA200901874B/xx unknown
- 2007-10-02 RU RU2009116653/15A patent/RU2489148C2/ru not_active IP Right Cessation
- 2007-10-02 EP EP07829383A patent/EP2089373A1/en not_active Withdrawn
- 2007-10-02 KR KR1020097006358A patent/KR101148805B1/ko not_active IP Right Cessation
- 2007-10-02 CA CA2665000A patent/CA2665000C/en not_active Expired - Fee Related
- 2007-10-02 MY MYPI20091324A patent/MY150229A/en unknown
- 2007-10-02 JP JP2009529959A patent/JP5068821B2/ja not_active Expired - Fee Related
- 2007-10-02 TW TW096136957A patent/TWI336699B/zh not_active IP Right Cessation
-
2009
- 2009-02-25 NO NO20090856A patent/NO20090856L/no not_active Application Discontinuation
- 2009-03-19 IL IL197723A patent/IL197723A/en not_active IP Right Cessation
- 2009-12-03 HK HK09111385.1A patent/HK1131619A1/xx not_active IP Right Cessation
-
2012
- 2012-06-18 US US13/526,283 patent/US20120322807A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL197723A (en) | 2015-02-26 |
BRPI0717218A2 (pt) | 2013-09-24 |
EP2089373A1 (en) | 2009-08-19 |
IL197723A0 (en) | 2009-12-24 |
KR101148805B1 (ko) | 2012-07-10 |
RU2009116653A (ru) | 2010-11-10 |
NO20090856L (no) | 2009-03-27 |
HK1131619A1 (en) | 2010-01-29 |
UA95978C2 (ru) | 2011-09-26 |
TW200823189A (en) | 2008-06-01 |
US8263599B2 (en) | 2012-09-11 |
AU2007305511A1 (en) | 2008-04-17 |
MX2009003256A (es) | 2009-04-08 |
TWI336699B (en) | 2011-02-01 |
CA2665000C (en) | 2015-03-24 |
JP2010505762A (ja) | 2010-02-25 |
US20100210661A1 (en) | 2010-08-19 |
ZA200901874B (en) | 2010-07-28 |
KR20090043008A (ko) | 2009-05-04 |
CN101522657B (zh) | 2014-10-15 |
JP5068821B2 (ja) | 2012-11-07 |
NZ598061A (en) | 2013-05-31 |
CN101522657A (zh) | 2009-09-02 |
RU2489148C2 (ru) | 2013-08-10 |
CA2665000A1 (en) | 2008-04-17 |
WO2008044667A1 (en) | 2008-04-17 |
MY150229A (en) | 2013-12-31 |
US20120322807A1 (en) | 2012-12-20 |
EP2612858A1 (en) | 2013-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063073A1 (es) | Inhibidor de la activacion de stat 3/5 | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
ATE428422T1 (de) | Piperidin-derivate als ccr3-antagonisten | |
DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
ECSP099371A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
ATE433981T1 (de) | Heterocyclische verbindungen | |
SE0401971D0 (sv) | Piperidne derivatives | |
UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
PE20050395A1 (es) | PROCEDIMIENTOS DE PREPARACION DE DERIVADOS DE ACIDO PIRROLIDIN-1,2-DICARBOXILICO-1-(FENIL(-AMIDA))-2-(FENIL(-AMIDA)) Y ACIDO-1-(FENILCARBAMOIL)-PIRROLIDIN-2-CARBOXILICO COMO INHIBIDORES DEL FACTOR Xa | |
NO20071108L (no) | Nye 4-benzylidenpiperidinderivater | |
ATE484508T1 (de) | Furylverbindungen | |
DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
SE0401970D0 (sv) | Novel compounds | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
AR076899A1 (es) | Derivados heterociclicos de la urea, composiciones farmaceuticas y su uso en el tratamiento de infecciones bacterianas | |
AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
SE0302546D0 (sv) | New compounds | |
UY29134A1 (es) | Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones | |
SE0203300D0 (sv) | Novel Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |